**ICMJE DISCLOSURE FORM**

**Date:** 28 July 28, 2021  
**Your Name:** Jingyuan Hou  
**Manuscript Title:** MicroRNA-146a-5p alleviates lipopolysaccharide-induced NLRP3 inflammasome injury and pro-inflammatory cytokine production via the regulation of TRAF6 and IRAK1 in human umbilical vein endothelial cells (HUVECs)  
**Manuscript number (if known):** ________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  
**No time limit for this item.** |  
**Time frame: Since the initial planning of the work**  
___ None  
National Natural Science Foundation for Young Scientists of China (grants no. 82002216)  
Medical Scientific Research Foundation of Guangdong Province (grants no. A2020418)  
Scientific Research and Cultivation Project of Meizhou People’s Hospital (grants no. C2019013) |
|   | Time frame: past 36 months |
|---|----------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | __×__None |
| 3 | Royalties or licenses | __×__None |
| 4 | Consulting fees | __×__None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | __×__None |
| 6 | Payment for expert testimony | __×__None |
| 7 | Support for attending meetings and/or travel | __×__None |
| 8 | Patents planned, issued or pending | __×__None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | __×__None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | __×__None |
| 11 | Stock or stock options | __×__None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | __×__None |
| 13 | Other financial or non-financial interests | __×__None |

Please summarize the above conflict of interest in the following box:

Jingyuan Hou reports support for the present manuscript from National Natural Science Foundation for Young Scientists of China (grants no. 82002216), Medical Scientific Research Foundation of Guangdong Province (grants no. A2020418), and Scientific Research and Cultivation Project of Meizhou People’s Hospital (grants no. C2019013).
Please place an “X” next to the following statement to indicate your agreement:

__ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 28 July 28, 2021
Your Name: Qiaoting Deng
Manuscript Title: MicroRNA-146a-5p alleviates lipopolysaccharide-induced NLRP3 inflammasome injury and pro-inflammatory cytokine production via the regulation of TRAF6 and IRAK1 in human umbilical vein endothelial cells (HUVECs)
Manuscript number (if known): ______________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **None**<br>Medical Scientific Research Foundation of Guangdong Province (grants no. A2021144)<br>Scientific Research and Cultivation Project of Meizhou People’s Hospital (grants no. PY-C2021010) |
|   | **Time frame: Since the initial planning of the work** | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | **× × None**<br>**× × None** |
| 3 | Royalties or licenses | **× × None**<br>**× × None** |

**Time frame: past 36 months**
|   | Description                                                                 | Agreement |
|---|------------------------------------------------------------------------------|-----------|
| 4 | Consulting fees                                                             | None      |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None      |
| 6 | Payment for expert testimony                                                  | None      |
| 7 | Support for attending meetings and/or travel                                  | None      |
| 8 | Patents planned, issued or pending                                            | None      |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board             | None      |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None      |
| 11| Stock or stock options                                                        | None      |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None      |
| 13| Other financial or non-financial interests                                     | None      |

Please summarize the above conflict of interest in the following box:

Qiaoting Deng reports support for the present manuscript from Medical Scientific Research Foundation of Guangdong Province (grants no. A2021144) and Scientific Research and Cultivation Project of Meizhou People’s Hospital (grants no. PY-C2021010).

Please place an “X” next to the following statement to indicate your agreement:

__ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 28 July 28, 2021
Your Name: Xunwei Deng
Manuscript Title: MicroRNA-146a-5p alleviates lipopolysaccharide-induced NLRP3 inflammasome injury and pro-inflammatory cytokine production via the regulation of TRAF6 and IRAK1 in human umbilical vein endothelial cells (HUVECs)
Manuscript number (if known): ____________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | __ × __None |

Time frame: Since the initial planning of the work

|   | Grants or contracts from any entity (if not indicated in item #1 above). | __ × __None |
|---|--------------------------------------------------------------------------|--------------|
| 2 | Royalties or licenses | __ × __None |
| 3 | Consulting fees | __ × __None |
| 4 |                                                                 |
|   | Description                                                                 | X | None |
|---|------------------------------------------------------------------------------|----|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events |    | None |
| 6 | Payment for expert testimony                                                   |    | None |
| 7 | Support for attending meetings and/or travel                                   |    | None |
| 8 | Patents planned, issued or pending                                             |    | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board              |    | None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |    | None |
| 11| Stock or stock options                                                         |    | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services |    | None |
| 13| Other financial or non-financial interests                                     |    | None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

__ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 28 July 28, 2021
Your Name: Wei Zhong
Manuscript Title: MicroRNA-146a-5p alleviates lipopolysaccharide-induced NLRP3 inflammasome injury and pro-inflammatory cytokine production via the regulation of TRAF6 and IRAK1 in human umbilical vein endothelial cells (HUVECs)
Manuscript number (if known): ____________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _×_None |
|   | **Time frame: Since the initial planning of the work** | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _×_None |
| 3 | Royalties or licenses | _×_None |
| 4 | Consulting fees | _×_None |
|   | **Time frame: past 36 months** | |
|   |                                                                                     | __×__None |
|---|-------------------------------------------------------------------------------------|-----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | __×__None |
| 6 | Payment for expert testimony                                                        | __×__None |
| 7 | Support for attending meetings and/or travel                                        | __×__None |
| 8 | Patents planned, issued or pending                                                   | __×__None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                   | __×__None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | __×__None |
|11 | Stock or stock options                                                              | __×__None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services    | __×__None |
|13 | Other financial or non-financial interests                                          | __×__None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

__ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 28 July 28, 2021
Your Name: Sudong Liu
Manuscript Title: MicroRNA-146a-5p alleviates lipopolysaccharide-induced NLRP3 inflammasome injury and pro-inflammatory cytokine production via the regulation of TRAF6 and IRAK1 in human umbilical vein endothelial cells (HUVECs)
Manuscript number (if known): ________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| # | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None |
|   | National Natural Science Foundation for Young Scientists of China (grants no. 82000410) | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |
| 4 | Consulting fees | None |
|   | Description                                                                 | X | None |
|---|-----------------------------------------------------------------------------|----|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,          | X  | None |
|   | manuscript writing or educational events                                    |    |      |
| 6 | Payment for expert testimony                                                | X  | None |
| 7 | Support for attending meetings and/or travel                                 | X  | None |
| 8 | Patents planned, issued or pending                                           | X  | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            | X  | None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy  | X  | None |
|   | group, paid or unpaid                                                        |    |      |
| 11| Stock or stock options                                                       | X  | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other      | X  | None |
|   | services                                                                     |    |      |
| 13| Other financial or non-financial interests                                   | X  | None |

Please summarize the above conflict of interest in the following box:

Sudong Liu reports support for the present manuscript from National Natural Science Foundation for Young Scientists of China (grants no. 82000410)

Please place an “X” next to the following statement to indicate your agreement:

__ X _  I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 28 July 28, 2021
Your Name: Zhixiong Zhong
Manuscript Title: MicroRNA-146a-5p alleviates lipopolysaccharide-induced NLRP3 inflammasome injury and pro-inflammatory cytokine production via the regulation of TRAF6 and IRAK1 in human umbilical vein endothelial cells (HUVECs)
Manuscript number (if known): 

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | __None |
| | Scientific Research and Cultivation Project of Meizhou People’s Hospital (grants no. PY-A2019001) | |
| **Time frame: past 36 months** | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | __×__None |
| 3 | Royalties or licenses | __×__None |
| 4 | Consulting fees | __×__None |
|   |                                                                 |     |
|---|----------------------------------------------------------------|-----|
| 5 | Payment or honoraria for lectures, presentations,             | __×__None |
|   | speakers bureaus, manuscript writing or educational events    |     |
| 6 | Payment for expert testimony                                  | __×__None |
| 7 | Support for attending meetings and/or travel                  | __×__None |
| 8 | Patents planned, issued or pending                            | __×__None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory   | __×__None |
|   | Board                                                        |     |
| 10| Leadership or fiduciary role in other board, society,         | __×__None |
|   | committee or advocacy group, paid or unpaid                   |     |
| 11| Stock or stock options                                       | __×__None |
| 12| Receipt of equipment, materials, drugs, medical writing,      | __×__None |
|   | gifts or other services                                       |     |
| 13| Other financial or non-financial interests                    | __×__None |

Please summarize the above conflict of interest in the following box:

Zhixiong Zhong reports support for the present manuscript from Scientific Research and Cultivation Project of Meizhou People’s Hospital (grants no. PY-A2019001).

Please place an “X” next to the following statement to indicate your agreement:

__ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.